扶正化瘀片联合西药治疗慢性肝炎肝硬化的临床疗效

发布时间：2018-04-16 23:10

本文选题：扶正化瘀片 + 慢性肝炎肝硬化　；参考：《辽宁中医杂志》2017年09期

【摘要】：目的:探究扶正化瘀片联合西药治疗慢性肝炎肝硬化的临床效果。方法:将2014年6月—2017年6月期间的156例慢性肝炎肝硬化患者随机分成两组,对照组采用替卡韦片治疗,观察组采用扶正化瘀片联合恩替卡韦治疗,比较两组患者血清血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)水平,肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平以及HBV-DNA载量。结果:治疗后,观察组患者血清血清AST、ALT水平,炎症介质TNF-α、IL-6和IL-8水平以及HBV-DNA载量均明显的低于对照组,HBV-DNA转阴率明显高于对照组,比较差异具有显著性(P0.05)。结论:扶正化瘀片联合恩替卡韦降低了肝脏炎症,提高了HBV-DNA转阴率,有效的改善了肝功能。
[Abstract]:Objective: to explore the clinical effect of Fuzheng Huayu tablet combined with western medicine in the treatment of chronic hepatitis cirrhosis.Methods: 156 patients with chronic hepatitis cirrhosis from June 2014 to June 2017 were randomly divided into two groups: the control group was treated with tekavir tablet, the observation group was treated with Fuzheng Huayu tablet combined with entecavir.The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (alt), tumor necrosis factor- 伪 (TNF- 伪), interleukin-6 (IL-6), interleukin-8 (IL-8) and HBV-DNA load were compared between the two groups.Results: after treatment, the levels of serum alt, TNF- 伪 IL-6, IL-8 and HBV-DNA load in the observation group were significantly lower than those in the control group, and the negative rate of HBV-DNA in the control group was significantly higher than that in the control group (P 0.05).Conclusion: Fuzheng Huayu tablet combined with entecavir can reduce liver inflammation, increase HBV-DNA negative rate and improve liver function effectively.
【作者单位】：新疆石河子大学医学院第一附属医院功能科;新疆石河子人民医院消化内科;新疆石河子大学医学院第一附属医院中医科;
【基金】：新疆维吾尔自治区自然科学基金(160030052)
【分类号】：R575

【相似文献】